On May 17, 2017 Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that new interim data from the first cohort of its ongoing Phase 2 study of LN-144 for the treatment of metastatic melanoma will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, IL from June 2-6, 2017 (Press release, Lion Biotechnologies, MAY 17, 2017, View Source [SID1234519207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very encouraged by this data as we have now demonstrated that we can manufacture TIL at our contract manufacturing organization partners and dose patients at multiple clinical sites with consistent results compared to available literature. The patients enrolled in this study are more treatment experienced than those enrolled in most of the previously published TIL clinical studies. The enrolled patients disclosed in the abstract have advanced metastatic melanoma, all refractory to both anti-PD-1 and CTLA-4 with a median of 3 prior therapies," said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Lion Biotechnologies. "We will be reporting data from additional patients in the current cohort at the conference as well."

Poster Title: Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-treated Metastatic Melanoma Patients Following Checkpoint Therapy
Poster Session Title: Developmental Therapeutics — Immunotherapy
Poster Board Number: 140
Date & Time: Monday, June 5, 2017 from 8:00 a.m. to 11:00 a.m. CT (9:00 a.m. to 12:00 p.m. ET)
Abstract Number: 3045
Location: Hall A
First author: Amod Sarnaik, MD

The data in the published abstract is from nine patients in cohort one who were infused as of January 31, 2017. These advanced metastatic melanoma patients are a median age of 56 and all had prior anti-PD1 as well as anti-CTLA4 therapy and 67 percent had received three or more prior therapies. The results show:

33% objective response rate
Responses were observed in patients with tumors carrying wild type or BRAF mutations
Eight of nine patients received all six doses of IL-2 per protocol
The most common (≥3 patients) non-hematologic grade 3-4 TEAE was hypophosphatemia
No neurotoxicity of grade 3 or higher was reported
There were no deaths or discontinuations due to SAEs related to study treatment
The accepted abstract is available online on ASCO (Free ASCO Whitepaper)’s website at View Source